Editorial response: Choosing amphotericin B formulations - Between a reck and a hard place

被引：10

作者：

Bennett, J ^{[1
]}

机构：

[1] NIAID, Clin Invest Lab, Clin Mycol Sect, NIH, Bethesda, MD 20854 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2000年 / 31卷 / 05期

关键词：

D O I：

10.1086/317443

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：1164 / 1165

页数：2

共 3 条

[1] Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia [J].

Walsh, TJ ;

Finberg, RW ;

Arndt, C ;

Hiemenz, J ;

Schwartz, C ;

Bodensteiner, D ;

Pappas, P ;

Seibel, N ;

Greenberg, RN ;

Dummer, S ;

Schuster, M ;

Holcenberg, JS .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (10) :764-771

[2] Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia [J].

White, MH ;

Bowden, RA ;

Sandler, ES ;

Graham, ML ;

Noskin, GA ;

Wingard, JR ;

Goldman, M ;

van Burik, JA ;

McCabe, A ;

Miller, CB ;

Gurwith, M ;

Carole, B .

CLINICAL INFECTIOUS DISEASES, 1998, 27 (02) :296-302

[3] A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia [J].

Wingard, JR ;

White, MH ;

Anaissie, E ;

Raffalli, J ;

Goodman, J ;

Arrieta, A .

CLINICAL INFECTIOUS DISEASES, 2000, 31 (05) :1155-1163

← 1 →